SCHEMBL14585385

SCHEMBL14585385

CN(C)CCCNc1nc(CN2CCN(C(=O)C3CCOC3)CC2)nc2ccccc12

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 4/20 0.48
▸ EHMT2 Q96KQ7 4/20 0.48
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ TERT O14746 3/20 0.43
▸ RAD52 P43351 4/20 0.41
▸ RCOR1 Q9UKL0 3/20 0.41
▸ POLB P06746 3/20 0.41
▸ TOP2A P11388 1/20 0.40
▸ FLT3 P36888 3/20 0.40
▸ KMT2A Q03164 2/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ SLC2A1 P11166 1/20 0.39
▸ APOBEC3A P31941 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ APOBEC3G Q9HC16 1/20 0.39
▸ ACP1 P24666 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14585382 0.91 KDM1A (0.53) KDM1AEHMT2ALDH1A1MAPK1TERT
SCHEMBL14585392 0.89 KDM1A (0.51) KDM1AEHMT2ALDH1A1MAPK1TERT
SCHEMBL14585380 0.88 KDM1A (0.51) KDM1AEHMT2ALDH1A1MAPK1TERT
SCHEMBL14585436 0.88 KDM1A (0.50) KDM1AEHMT2ALDH1A1MAPK1TERT
SCHEMBL14585407 0.87 KDM1A (0.49) KDM1AEHMT2ALDH1A1MAPK1TERT
SCHEMBL14585381 0.85 ALDH1A1 (0.55) KDM1AEHMT2ALDH1A1MAPK1TERT
SCHEMBL14585421 0.85 KDM1A (0.47) KDM1AEHMT2ALDH1A1MAPK1TERT
SCHEMBL14585377 0.84 ALDH1A1 (0.52) KDM1AEHMT2ALDH1A1MAPK1TERT
SCHEMBL14585376 0.84 KDM1A (0.52) KDM1AEHMT2ALDH1A1MAPK1TERT
SCHEMBL14628129 0.83 KDM1A (0.51) KDM1AEHMT2ALDH1A1MAPK1TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032502-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-02-08 — — US disclosed
US-20070032502-A1 Quinazoline derivatives useful in cancer treatment SCHERING CORPORATION 2007-02-08 — — US disclosed
WO-2007011623-A1 QUINAZOLINE DERIVATIVES USEFUL IN CANCER TREATMENT SCHERING CORPORATION (US) 2007-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032502-A1 Quinazoline derivatives useful in cancer treatment TP53, ACIN1, TP53BP1 KDM1A 1966/4885EHMT2 3519/4885ALDH1A1 2874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback